Brief: Oncolys BioPharma applies phase II clinical trial of OBP-301 in U.S
31/08/2016 07:27
Aug 31 (Reuters) - Oncolys BioPharma Inc 4588.T :
* Says it submitted clinical trial plan (protocol) to the
United States Food and Drug Administration for phase II clinical
trial of oncolytic virus OBP-301 (Telomelysin) in U.S
* Says unresectable or metastatic malignant melanoma is the
target of the clinical trial
Source text in Japanese: https://goo.gl/EqEsKO
Further company Coverage: 4588.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))